References
- Fox KAA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ [Internet]. 2006 Nov 25 [cited 2018 May 26];333(7578):1091. Available from: http://www.bmj.com/lookup/doi/10.1136/bmj.38985.646481.55
- Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med [Internet]. 2011 Jan 20;364(3):226–235. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21247313
- Gibson CM, Korjian S, Tricoci P, et al. Rationale and design of Apo-I event reduction in ischemic syndromes I (AEGIS-I): a phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. Am Heart J [Internet]. 2016 Oct [cited 2018 May 26];180:22–28. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002870316301089
- Bounafaa A, Berrougui H, Ikhlef S, et al. Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients. Clin Biochem [Internet]. 2014 Dec;47(18):318–325. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25218815
- Shao B, Tang C, Sinha A, et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res [Internet]. 2014 May 23;114(11):1733–1742. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24647144
- HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med [Internet]. 2014 Jul 17 [cited 2018 May 26];371(3):203–212. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25014686
- Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med [Internet]. 2011 Dec 15 [cited 2018 May 26];365(24):2255–2267. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1107579
- Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med [Internet]. 2007 Nov 22 [cited 2018 May 26];357(21):2109–2122. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0706628
- Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med [Internet]. 2012 Nov 29 [cited 2018 May 26];367(22):2089–2099. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1206797
- Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med [Internet]. 2017 Sep 28;377(13):1217–1227. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1706444
- Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (London, England) [Internet]. 2012 Aug 11;380(9841):572–580. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22607825
- Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med [Internet]. 2014 Dec 18 [cited 2018 May 26];371(25):2383–2393. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1409065
- Diditchenko S, Gille A, Pragst I, et al. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler Thromb Vasc Biol [Internet]. 2013 Sep 1 [cited 2018 May 26];33(9):2202–2211. Available from: http://atvb.ahajournals.org/cgi/doi/10.1161/ATVBAHA.113.301981
- Roffi M, Patrono C, Collet J-P, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of. Eur Heart J [Internet]. 2016 Jan 14 [cited 2017 Oct 7];37(3):267–315. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehv320
- Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation [ Internet]. 2014 Dec 23 [cited 2017 Dec 28];130(25):e344–426. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25249585
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med [Internet]. 2015 Jun 18;372(25):2387–2397. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1410489
- Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med [Internet]. 2015 Apr 16;372(16):1489–1499. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1501031
- Steg GP Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab - ODYSSEY OUTCOMES. Present Am Coll Cardiol Annu Sci Sess (ACC 2018); March 10, 2018; Orlando, FL.
- Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representati. Eur Hear J [Internet]. 2016;37(29):2315–2381. Societie: European Society of Cardiology (ESC). International Society of Behavioural Medicine (ISBM). WONCA Europe. Societie: European Atherosclerosis Society (EAS). International Diabetes Federation European Region (IDF Europe). International Federation; Available from: https://www.ncbi.nlm.nih.gov/pubmed/27222591
- Javaheri A, Kolansky DM, Cuchel M. Reconstituted high-density lipoprotein therapies: a cause for optimism. Arterioscler Thromb Vasc Biol [Internet]. 2014 Sep 1;34(9):1800–1802. Available from: http://atvb.ahajournals.org/cgi/doi/10.1161/ATVBAHA.114.304156
- Gille A, Easton R, D’Andrea D, et al. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler Thromb Vasc Biol [Internet]. 2014 Sep 1 [cited 2018 May 26];34(9):2106–2114. Available from: http://atvb.ahajournals.org/cgi/doi/10.1161/ATVBAHA.114.303720
- Gille A, D’Andrea D, Tortorici MA, et al. CSL112 (Apolipoprotein A-I [Human]) enhances cholesterol efflux similarly in healthy individuals and stable atherosclerotic disease patients. Arterioscler Thromb Vasc Biol [Internet]. 2018 Apr [cited 2018 May 26];38(4):953–963. Available from: http://atvb.ahajournals.org/lookup/doi/10.1161/ATVBAHA.118.310538
- Gurbel PA, Tantry US, D’Andrea D, et al. Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. J Thromb Thrombolysis [Internet]. 2018 May 26 [cited 2018 May 26];45(4):469–476. Available from: http://link.springer.com/10.1007/s11239-018-1644-z
- Easton R, Gille A, D’Andrea D, et al. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J Clin Pharmacol [Internet]. 2014 Mar [cited 2018 May 26];54(3):301–310. Available from: http://doi.wiley.com/10.1002/jcph.194
- Tricoci P, D’Andrea DM, Gurbel PA, et al. Infusion of reconstituted high-density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a phase 2a randomized clinical trial. J Am Heart Assoc [Internet]. 2015 Aug 25 [cited 2018 May 26];4(8):e002171. Available from: http://jaha.ahajournals.org/lookup/doi/10.1161/JAHA.115.002171
- Gibson MC, Korjian S, Tricoci P, et al. Safety and Tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (apoa-i event reducing in ischemic syndromes I). Circulation [Internet]. 2016 Dec 13 [cited 2018 May 26];134(24):1918–1930. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27881559
- Bauer L, Kern S, Rogacev KS, et al. HDL cholesterol efflux capacity and cardiovascular events in patients with chronic kidney disease. J Am Coll Cardiol [Internet]. 2017 Jan 17;69(2):246–247. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28081833
- Chindhy S, Joshi P, Khera A, et al. Impaired renal function on cholesterol efflux capacity, HDL particle number, and cardiovascular events. J Am Coll Cardiol [Internet]. 2018 Aug 7;72(6):698–700. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30072004
- Gibson CM, Yee M, Daaboul Y, et al. The safety and tolerability of multiple dose administration of Csl112, an intravenous formulation of plasma-derived Apoa-I, among subjects with moderate renal impairment after acute myocardial infarction. J Am Coll Cardiol [Internet]. 2018 Mar;71(11):A165. Available from: http://linkinghub.elsevier.com/retrieve/pii/S073510971830706X
- Du X-M, Kim M-J, Hou L, et al. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res [Internet]. 2015 Mar 27;116(7):1133–1142. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25589556
- Feig JE, Hewing B, Smith JD, et al. High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res [Internet]. 2014 Jan 3;114(1):205–213. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24385513
- Tardif J-C, Ballantyne CM, Barter P, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J [Internet]. 2014 Dec 7;35(46):3277–3286. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24780501
- Nicholls SJ, Andrews J, Kastelein JJP, et al. Effect of serial infusions of CER-001, a pre-β high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical tria. JAMA Cardiol [Internet]. 2018 Sep 1;3(9):815–822. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30046828
- Nicholls SJ, Puri R, Ballantyne CM, et al. Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT trial: a randomized clinical trial. JAMA Cardiol [Internet]. 2018 Sep 1;3(9):806–814. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30046837
- Karalis I, Jukema JW. HDL mimetics infusion and regression of atherosclerosis: is it still considered a valid therapeutic option? Curr Cardiol Rep [Internet]. 2018 Jun 21;20(8):66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29926215
- Rader DJ. Apolipoprotein A-I infusion therapies for coronary disease: two outs in the ninth inning and swinging for the fences. JAMA Cardiol [Internet]. 2018 Sep 1;3(9):799–801. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30046821
- Didichenko SA, Navdaev AV, Cukier AMO, et al. Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity. Circ Res [Internet]. 2016 Sep 2 [cited 2018 May 26];119(6):751–763. Available from: http://circres.ahajournals.org/lookup/doi/10.1161/CIRCRESAHA.116.308685